Picture of Inovio Pharmaceuticals logo

INO — Inovio Pharmaceuticals News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Inovio Pharmaceuticals Inc expected to post a loss of 14 cents a share - Earnings Preview

* Inovio Pharmaceuticals Inc  INO.OQ   INO.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 10. 
    * The San Diego California-based  company is expected to
report  a
38.1% increase in revenue to $275 thousand from $199.07 thousand
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Inovio
Pharmaceuticals
Inc is for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inovio
Pharmaceuticals Inc is $1.2​, above​ its last closing price
of $0.82. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.17       -0.17      -0.21     Missed  -25
 Sep. 30 2022  -0.30       -0.30      -0.15     Beat    49.3
 Jun. 30 2022  -0.31       -0.31      -0.46     Missed  -47.6​
 Mar. 31 2022  -0.32       -0.34      -0.36     Missed  -4.9
 ​​Dec.        -0.33       -0.32      -0.50     Missed  -56.8
 31 2021                                                
 Sep. 30 2021  -0.33       -0.33      -0.29     Beat    11​
 Jun. 30 2021  -0.25       -0.25      -0.39     Missed  -56.6
 Mar. 31 2021  -0.18       -0.18      -0.27     Missed  -48.8
 This summary was machine generated May 8 at 21:01 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Inovio Pharmaceuticals

See all news